Brief Report - (2025) Volume 15, Issue 3
Received: 01-May-2025, Manuscript No. jccr-25-170750;
Editor assigned: 03-May-2025, Pre QC No. P-170750;
Reviewed: 15-May-2025, QC No. Q-170750;
Revised: 22-May-2025, Manuscript No. R-170750;
Published:
29-May-2025
, DOI: 10.37421-2165-7920.2025.15.1659
Citation: Nobles, Ells. “Prognostic and Early Detection Biomarkers for Lung Diseases.” J Clin Case Rep 15 (2025): 1659.
Copyright: © 2025 Nobles E. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
In the realm of lung cancer, biomarkers have played a pivotal role in shifting clinical practice toward precision medicine. Circulating tumor DNA (ctDNA), exosomal microRNAs and specific protein signatures are being investigated as tools for detecting malignancies at early stages. For example, epidermal growth factor receptor (EGFR) mutations and ALK rearrangements not only aid in diagnosis but also predict therapeutic response to targeted agents. Liquid biopsies, which analyze ctDNA or circulating tumor cells from blood samples, offer a minimally invasive approach for disease monitoring and prognostication. These biomarkers are particularly valuable in detecting minimal residual disease and relapse, guiding timely therapeutic interventions. Prognostic markers such as PD-L1 expression further help predict immunotherapy outcomes, enabling tailored treatment plans for patients with lung cancer [2].
In Chronic Obstructive Pulmonary Disease (COPD), biomarkers are increasingly recognized as essential for identifying disease phenotypes and progression risks. Traditional spirometry remains useful but insufficient in capturing the heterogeneity of COPD. Biomarkers such as fibrinogen, C - reactive protein (CRP) and Surfactant Protein D (SP-D) have been linked to systemic inflammation and lung tissue injury. Elevated levels of fibrinogen, for example, are associated with higher mortality and exacerbation frequency, making it a candidate for prognostic evaluation. Blood eosinophil counts have also gained prominence as predictive markers for corticosteroid responsiveness in COPD patients. By integrating such biomarkers into clinical practice, physicians can move beyond generalized treatment approaches and instead employ personalized management strategies aimed at reducing exacerbations and disease progression [3].
Interstitial Lung Diseases (ILDs), particularly Idiopathic Pulmonary Fibrosis (IPF), highlight the urgent need for reliable prognostic and diagnostic biomarkers. Circulating markers such as KL-6, surfactant protein A (SP-A) and SP-D have been studied extensively, with elevated levels correlating with disease activity and progression. Genetic biomarkers, including mutations in the MUC5B promoter and telomerase-related genes, are strongly associated with susceptibility and prognosis in IPF. Imaging-based biomarkers derived from High-Resolution Computed Tomography (HRCT) combined with molecular data further enhance predictive accuracy. These tools enable clinicians to detect disease before significant lung scarring occurs, facilitating early initiation of antifibrotic therapy. Importantly, prognostic biomarkers in ILD also help stratify patients for clinical trials and therapeutic decision-making, ensuring optimal use of available treatments [4].
Beyond individual disease categories, several cross-cutting biomarkers have shown potential across multiple lung conditions. For example, microRNAs (miRNAs) regulate gene expression involved in inflammation, fibrosis and carcinogenesis, making them promising candidates for broad biomarker panels. Circulating extracellular vesicles (EVs) and metabolomic signatures are emerging as innovative biomarkers with the potential to capture the complexity of lung pathophysiology. Proteomic and transcriptomic profiling allows for multi-biomarker signatures that can distinguish between overlapping conditions such as COPD and asthma or between benign and malignant pulmonary nodules. The integration of artificial intelligence and machine learning with biomarker data is also enhancing predictive accuracy, allowing for earlier and more reliable detection. These advances highlight a paradigm shift from single biomarker approaches toward multi-omics strategies for precision lung disease management [5].
Google Scholar Cross Ref Indexed at
Google Scholar Cross Ref Indexed at
Google Scholar Cross Ref Indexed at
Google Scholar Cross Ref Indexed at
Journal of Clinical Case Reports received 1345 citations as per Google Scholar report